bluebird bio (BLUE) to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress

May 13, 2021 8:07 AM EDT
Get Alerts BLUE Hot Sheet
Price: $33.15 +0.52%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

bluebird bio, Inc. (Nasdaq: BLUE) announced today that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) and its cell therapy program for relapsed or refractory multiple myeloma (R/RMM) will be presented during EHA2021 Virtual, the 26th Annual Congress of the European Hematology Association, taking place June 9-17, 2021.

bluebird bio will present data from its ongoing clinical studies of betibeglogene autotemcel (beti-cel), including updated results from the Phase 3 Northstar-2 (HGB-207) and the Phase 3 Northstar-3 (HGB-212) studies, as well as long-term efficacy and safety results from the LTF-303 follow-up study. Additionally, data from the company’s Phase 1/2 HGB-206 study of LentiGlobin for SCD (bb1111) will be shared.

Data from the pivotal Phase 2 KarMMa study of ABECMA® (idecabtagene vicleucel; ide-cel) in R/RMM will also be presented in encore presentations, in partnership with Bristol Myers Squibb, including long-term results and a sub-analysis of characteristics of treatment-associated neurotoxicity.

Transfusion-Dependent β-Thalassemia Data at EHA2021

Oral Presentation [S266]: Betibeglogene autotemcel in Patients With Transfusion-Dependent β-Thalassemia: Updated Results From HGB-207 (Northstar-2) and HGB-212 (Northstar-3)
Presenting Author:
Professor Franco Locatelli, Director, Department of Pediatric Hematology and Oncology, Ospedale Pediatrico Bambino Gesù, Rome, Italy
Session Title: Changing the Scene on Thalassemias
Date & Time: Available on Demand, Friday, June 11; Live Q&A Session

Oral Presentation [S257]: Betibeglogene autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia: Updated Long-Term Efficacy and Safety Results
Presenting Author:
Dr. Evangelia Yannaki, Director, Gene and Cell Therapy Center, Hematology Department, George Papanicolaou Hospital, Thessaloniki, Greece
Session Title: Cellular Immunotherapy and Gene Therapy – Clinical
Date & Time: Available on Demand, Friday, June 11; Live Q&A Session

ePoster [EP1301]: Interim Results of Betibeglogene autotemcel Gene Therapy in Pediatric Patients with Transfusion-Dependent β-thalassemia (TDT) Treated in the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) Studies
Presenting Author:
Dr. Andreas E. Kulozik, Chairman, Department of Pediatric Oncology, Hematology and Immunology, and Director, Hopp Children's Cancer Center, University of Heidelberg, Heidelberg, Germany

ePoster [EP1309]: A Retrospective Database Study of Disease Course and Clinical Outcomes in Patients with Transfusion-dependent Thalassemia (TDT) in Italy
Presenting Author:
Dr. Angela Vitrano, Campus of Hematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervello, Palermo, Italy

Sickle Cell Disease Data at EHA2021

Oral Presentation [S261]: Complete Resolution of Severe Vaso-Occlusive Events and Improved Pathophysiology with LentiGlobin Gene Therapy in Sickle Cell Disease (SCD): Ongoing Phase 1/2 HGB-206 Group C Study
Presenting Author:
Dr. Janet L. Kwiatkowski, Director, Thalassemia Center at Children's Hospital of Philadelphia, Philadelphia, PA
Session Title: Changing the Scene on Sickle Cell Disease
Date & Time: Available on Demand, Friday, June 11; Live Q&A Session

ePoster [EP1212]: Complications of Sickle Cell Disease in East London Newborn Cohort Patients Over the Years 2015-2018
Presenting Author:
Muriel Soriano, Centre of Genomics and Child Health, Queen Mary University of London, London, United Kingdom

Multiple Myeloma Data at EHA2021

ePoster [EP984]: Characteristics of Neurotoxicity Associated with Idecabtagene Vicleucel (ide-cel, bb2121) in Patients with Relapsed and Refractory Multiple Myeloma in the Pivotal Phase II KarMMa Study
Presenting Author:
Dr. Salomon Manier, Department of Hematology, Lille University Hospital, Lille, France

ePoster [EP1009]: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated KarMMa Results
Presenting Author:
Dr. Albert Oriol, Institut Josep Carreras and Institut Catala d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain

Abstracts are available on the EHA2021 conference website.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Related Entities

Earnings, FDA